bpc 157 fda warning news 2025 Regulatory Alert: FDA's April 2026 Update on BPC-157 and GHK-Cu – Holt Law An FDA Committee Just Voted

The chronic use of any of these medications has the potential to cause complications related to vitamin B12 deficiency, which includes impaired DNA synthesis, impaired cell division, hematopoiesis, hyperhomocysteinemia, and metabolism of odd-chain fatty acids that is necessary in preventing demyelination of nerves

What distinguishes responders from non-responders

Must be handled by qualified research professionals

Once in the bloodstream, cibinetide binds this receptor on immune cells (especially myeloid cells like macrophages and microglia), endothelial cells, and other stressed tissues, triggering intracellular signaling (e.g., JAK/STAT, PI3K/Akt, and inhibition of NF-B p65) that dampens innate immune overactivation, suppresses production and systemic release of pro-inflammatory cytokines (TNF-, IL-1, IL-6, IL-12/IL-23), reduces chemokine-driven cell infiltration, lowers oxidative stress and nitric oxide overproduction, and promotes anti-inflammatory shifts and cell survival

TOP Diagnosis B 12 Testing Routine B 12 screening is not supported by the current body of evidence